Ⅰ期肺腺癌中类干细胞 CD8 T 细胞作为预后生物标志物的初步研究。

Stem-like CD8 T cells in stage I lung adenocarcinoma as a prognostic biomarker: A preliminary study.

机构信息

Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, China.

Department of Pathology, The Affiliated Taian City Central Hospital of Qingdao University, Taian, China.

出版信息

J Cancer Res Ther. 2024 Apr 1;20(2):669-677. doi: 10.4103/jcrt.jcrt_2453_23. Epub 2024 Apr 30.

DOI:10.4103/jcrt.jcrt_2453_23

PMID:38687939

Abstract

OBJECTIVES

This study aimed to investigate the presence of stem-like CD8 T (CD8 TSL) cells in lung adenocarcinoma (LUAD) and explore their relationships with the clinical outcomes.

METHODS

Multiplex immunofluorescence (mIF) was performed to identify CD8 TSL and antigen-presenting cells (APC) in 76 LUAD patients. Differences in the number of CD8 TSL cells based on tumor stage and the spatial relationships between CD8 TSL cells and APC niches were determined. The optimal cutoff value of CD8 TSL cells for predicting survival in patients with stage I LUAD was calculated.

RESULTS

CD8 TSL cells were present in all tumors, and their numbers were significantly higher in stage I patients than in stage III patients (P = 0.010); CD8 TSL cells located in the APC niches accounted for 69.7% (53/76) of the hotspot fields. The optimal cutoff value for the number of CD8 TSL cells required to predict the overall survival (OS) in patients with stage I LUAD was 2.5 per 10000 μm2. The median OS and progression-free survival (PFS) in the high-level group (>2.5) were significantly (P < 0.001) longer than those in the low-level group (≤2.5). The number of CD8 TSL cells was an independent prognostic factor for stage I LUAD. Patients with more CD8 TSL cells had a lower risk of death and disease progression than those with less CD8 TSL cells.

CONCLUSION

CD8 TSL cells were observed in patients with stages I-III LUAD and might serve as prognostic biomarkers for stage I LUAD.

摘要

目的

本研究旨在探讨肺腺癌（LUAD）中是否存在干细胞样 CD8 T（CD8 TSL）细胞，并探索其与临床结局的关系。

方法

采用多重免疫荧光（mIF）技术在 76 例 LUAD 患者中鉴定 CD8 TSL 和抗原呈递细胞（APC）。根据肿瘤分期和 CD8 TSL 细胞与 APC 龛之间的空间关系，确定 CD8 TSL 细胞数量的差异。计算预测 I 期 LUAD 患者生存的 CD8 TSL 细胞最佳截断值。

结果

所有肿瘤均存在 CD8 TSL 细胞，且 I 期患者的数量明显高于 III 期患者（P=0.010）；位于 APC 龛内的 CD8 TSL 细胞占热点视野的 69.7%（53/76）。预测 I 期 LUAD 患者总生存期（OS）所需的 CD8 TSL 细胞数量最佳截断值为每 10000μm² 2.5 个。高水平组（>2.5）的中位 OS 和无进展生存期（PFS）明显长于低水平组（≤2.5）（P<0.001）。CD8 TSL 细胞数量是 I 期 LUAD 的独立预后因素。CD8 TSL 细胞数量较多的患者死亡和疾病进展的风险低于 CD8 TSL 细胞数量较少的患者。